Special Issues around Veterinary Vaccines

Vaccines for Biodefense and Emerging and Neglected Diseases

Volumn , Issue , 2009, Pages 225-254

  Adams, L Garry ^a   Babiuk, Lorne ^b   McGavin, David ^c   Nordgren, Robert ^d  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ZOETIS   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876497680     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-369408-9.00016-0     Document Type: Chapter

References (206)

1. Agin T.S., Zhu C., Johnson L.A., Thate T.E., Yang Z., Boedeker E.C. Protection against hemorrhagic colitis in an animal model by oral immunization with isogeneic rabbit enteropathogenic Escherichia coli attenuated by truncating intimin. Infect. Immun. 2005, 73(10):6608-6619.
2. Alves M., Matos O., Antunes F. Multilocus PCR-RFLP analysis of Cryptosporidium isolates from HIV-infected patients from Portugal. Ann. Trop. Med. Parasitol. 2001, 95(6):627-632.
3. Andrianov A.K., Chen J., Payne L.G. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials 1998, 19(1-3):109-115.
4. Compendium of measures to prevent disease associated with animals in public settings. MMWR 2005, 1277-1280. Anonymous.
5. Anonymous. Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food. CDC, 2005c; 54:352-356.
6. Anonymous. Division of Bacterial and Mycotic Diseases. CDC. 2006. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/escherichiacoli_g.htm.
7. Armson A., Meloni B.P., Reynoldson J.A., Thompson R.C. Assessment of drugs against Cryptosporidium parvum using a simple in vitro screening method. FEMS Microbiol. Lett. 1999, 178(2):227-233.
8. Babiuk L.A., Babiuk S.L., Baca-Estrada M.E. Novel vaccine strategies. Adv. Virus Res. 2002, 58:29-80.
9. Babiuk L.A., Babiuk S.L., Loehr B.I., van Drunnen Littel-van den H. Nucleic acid vaccines: research tool or commercial reality. Vet. Immunol. Immunopathol. 2000, 76(1-2):1-23.
10. Barnes D.A., Bonnin A., Huang J.X., Gousset L., Wu J., Gut J., Doyle P., Dubremetz J.F., Ward H., Petersen C. A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion. Mol. Biochem. Parasitol. 1998, 96(1-2):93-110.
11. Bates T.W., Carpenter T.E., Thurmond M.C. Benefit-cost analysis of vaccination and preemptive slaughter as a means of eradicating foot-and-mouth disease. Am. J. Vet. Res. 2003, 64(7):805-812.
12. Bates T.W., Thurmond M.C., Carpenter T.E. Description of an epidemic simulation model for use in evaluating strategies to control an outbreak of foot-and-mouth disease. Am. J. Vet. Res. 2003, 64(2):195-204.
13. Bates T.W., Thurmond M.C., Carpenter T.E. Results of epidemic simulation modeling to evaluate strategies to control an outbreak of foot-and-mouth disease. Am. J. Vet. Res. 2003, 64(2):205-210.
14. Belton D.J. The macro-economic impact of a foot-and-mouth disease incursion in New Zealand. Dev. Biol. (Basel) 2004, 119:457-461.
15. Benoit M.A., Baras B., Gillard J. Preparation and characterization of protein-loaded poly(epsilon-caprolactone) microparticles for oral vaccine delivery. Int. J. Pharm. 1999, 184(1):73-84.
16. Berthelot-Herault F., Gottschalk M., Morvan H., Kobisch M. Dilemma of virulence of Streptococcus suis: Canadian isolate 89-1591 characterized as a virulent strain using a standardized experimental model in pigs. Can. J. Vet. Res. 2005, 69(3):236-240.
17. Bishai D., Lin M.K., Kiyonga C.W. Modeling the economic benefits of an AIDS vaccine. Vaccine 2001, 20(3-4):526-531.
18. Bishai D.M., Mercer D. Modeling the economic benefits of better TB vaccines. Int. J. Tuberc. Lung. Dis. 2001, 5(11):984-993.
19. Bowersock T.L., HogenEsch H., Suckow M., Guimond P., Martin S., Borie D., Torregrosa S., Park H., Park K. Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine 1999, 17(13-14):1804-1811.
20. Branscum A.J., Perez A.M., Johnson W.O., Thurmond M.C. Bayesian spatiotemporal analysis of foot-and-mouth disease data from the Republic of Turkey. Epidemiol. Infect. 2008, 136(6):833-842.
21. Brochier B., Costy F., Pastoret P.P. Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: an update. Vet. Microbiol. 1995, 46(1-3):269-279.
22. Brochier B., Kieny M.P., Costy F., Coppens P., Bauduin B., Lecocq J.P., Languet B., Chappuis G., Desmettre P., Afiademanyo K., et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991, 354(6354):520-522.
23. Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev. Biol. Stand. 1993, 81:103-107.
24. Burton G., Mason K.V. Do postvaccinal sarcomas occur in Australian cats?. Aust. Vet. J. 1997, 75(2):102-106.
25. Busque P., Higgins R., Caya F., Quessy S. Immunization of pigs against Streptococcus suis serotype 2 infection using a live avirulent strain. Can. J. Vet. Res. 1997, 61(4):275-279.
26. Capua I. Vaccination for notifiable avian influenza in poultry. Rev. Sci. Tech. 2007, 26(1):217-227.
27. Cawthraw S., Ayling R., Nuijten P., Wassenaar T., Newell D.G. Isotype, specificity, and kinetics of systemic and mucosal antibodies to Campylobacter jejuni antigens, including flagellin, during experimental oral infections of chickens. Avian Dis. 1994, 38(2):341-349.
28. Claesson B.A., Trollfors B., Lagergard T., Taranger J., Bryla D., Otterman G., Cramton T., Yang Y., Reimer C.B., Robbins J.B., et al. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J. Pediatr. 1988, 112(5):695-702.
29. Clavijo A., Wright P., Kitching P. Developments in diagnostic techniques for differentiating infection from vaccination in foot-and-mouth disease. Vet. J. 2004, 167(1):9-22.
30. Cleland J.L., Lim A., Daugherty A., Barron L., Desjardin N., Duenas E.T., Eastman D.J., Vennari J.C., Wrin T., Berman P., Murthy K.K., Powell M.F. Development of a single-shot subunit vaccine for HIV-1. 5. Programmable in vivo autoboost and long lasting neutralizing response. J. Pharm. Sci. 1998, 87(12):1489-1495.
31. Cox J.C., Coulter A.R. Adjuvants: a classification and review of their modes of action. Vaccine 1997, 15(3):248-256.
32. Cox J.C., Sjolander A., Barr I.G. ISCOMs and other saponin based adjuvants. Adv. Drug Deliv. Rev. 1998, 32(3):247-271.
33. de Greeff A., Buys H., Verhaar R., Dijkstra J., van Alphen L., Smith H.E. Contribution of fibronectin-binding protein to pathogenesis of Streptococcus suis serotype 2. Infect. Immun. 2002, 70(3):1319-1325.
34. Dean-Nystrom E.A., Gansheroff L.J., Mills M., Moon H.W., O'Brien A.D. Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect. Immun. 2002, 70(5):2414-2418.
35. DeHaven, R. Veterinary Services Memorandum No. 800.202-General Licensing Considerations: Efficacy Studies (U.S.D.o. Agriculture, Ed.), 2002.
36. Deneer H.G., Potter A.A. Effect of iron restriction on the outer membrane proteins of Actinobacillus ( Haemophilus) pleuropneumoniae. Infect. Immun. 1989, 57(3):798-804.
37. Deneer H.G., Potter A.A. Iron-repressible outer-membrane proteins of Pasteurella haemolytica. J. Gen. Microbiol. 1989, 135(Pt 2):435-443.
38. Deng W., Puente J.L., Gruenheid S., Li Y., Vallance B.A., Vazquez A., Barba J., Ibarra J.A., O'Donnell P., Metalnikov P., Ashman K., Lee S., Goode D., Pawson T., Finlay B.B. Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(10):3597-3602.
39. Descamps, J., Charlier, P., Jolie, R. and Roose, P.D. International Pig Veterinary Society, 11th Congress, Lausanne, Switzerland. 1990.
40. Diwan M., Tafaghodi M., Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control. Release 2002, 85(1-3):247-262.
41. Domenech J., Lubroth J., Eddi C., Martin V., Roger F. Regional and international approaches on prevention and control of animal transboundary and emerging diseases. Ann. N.Y. Acad. Sci. 2006, 1081:90-107.
42. Donnenberg M.S., Kaper J.B. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect. Immun. 1991, 59(12):4310-4317.
43. Eldridge J.H., Staas J.K., Chen D., Marx P.A., Tice T.R., Gilley R.M. New advances in vaccine delivery systems. Semin. Hematol. 1993, 30(Suppl. 4):16-24. discussion 25.
44. Enriquez F.J., Riggs M.W. Role of immunoglobulin A monoclonal antibodies against P23 in controlling murine Cryptosporidium parvum infection. Infect. Immun. 1998, 66(9):4469-4473.
45. Evans S.J., Sayers A.R. A longitudinal study of campylobacter infection of broiler flocks in Great Britain. Prev. Vet. Med. 2000, 46(3):209-223.
46. Fayer R., Fetterer R. Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice. J. Parasitol. 1995, 81(5):794-795.
47. Ferguson M., Wood D.J., Minor P.D. Antigenic structure of poliovirus in inactivated vaccines. J. Gen. Virol. 1993, 74(Pt 4):685-690.
48. Frick K.D., Colchero M.A., Dean D. Modeling the economic net benefit of a potential vaccination program against ocular infection with Chlamydia trachomatis. Vaccine 2004, 22(5-6):689-696.
49. Gaertner F.H., Babiuk L.A., Van Moorlehem E.A., Beskorwayne T.K., Lee S.L., Shutter R.W., Armstrong J.M., Griebel P.J. Amended recombinant cells (ARCs): an economical and surprisingly effective production and delivery vehicle for recombinant bovine IFN-gamma. J. Control. Release 2005, 107(2):189-202.
50. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 2001, 13(1):114-119.
51. Garner M.G., Whan I.F., Gard G.P., Phillips D. The expected economic impact of selected exotic diseases on the pig industry of Australia. Rev. Sci. Tech. 2001, 20(3):671-685.
52. Garrity, G.M. Bergey's Manual of Systematic Bacteriology. In: (Boone, D.R. and Castenholz, R.W., Eds.), 2nd, New York: Springer, 2005.
53. Gast R.K. Paratyphoid infections. Diseases of Poultry 2003, 583-613. Iowa State Press, Ames. IA. Y.M. Saif, H.J. Barnes, J.R. Glisson, A.M. Fadly, L.R. McDougald, D.E. Swayne (Eds.).
54. Gerdts V., Mutwiri G.K., Tikoo S.K., Babiuk L.A. Mucosal delivery of vaccines in domestic animals. Vet. Res. 2006, 37(3):487-510.
55. Giavedoni L., Ahmad S., Jones L., Yilma T. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J. Virol. 1997, 71(2):866-872.
56. Gomez M., Correa J.M. Haemagglutination-inhibiting antibodies and resistance to challenge in fowls following aerosol vaccination against Newcastle disease. Arch. Med. Vet. 1978, 10(2):128-135.
57. Gomis S., Babiuk L., Allan B., Willson P., Waters E., Ambrose N., Hecker R., Potter A. Protection of neonatal chicks against a lethal challenge of Escherichia coli using DNA containing cytosine-phosphodiester-guanine motifs. Avian Dis. 2004, 48(4):813-822.
58. Gough R.E., Allan W.H. Aerosol vaccination against Newcastle disease: the influence of vaccine diluent. Vet. Rec. 1973, 93(17):458-461.
59. Greensfelder L. Infectious diseases. Polio outbreak raises questions about vaccine. Science 2000, 290(5498):1867-1869.
60. Gruening P., Fulde M., Valentin-Weigand P., Goethe R. Structure, regulation, and putative function of the arginine deiminase system of Streptococcus suis. J. Bacteriol. 2006, 188(2):361-369.
61. Gust I.D., Hampson A.W., Lavanchy D. Planning for the next pandemic of influenza. Rev. Med. Virol. 2001, 11(1):59-70.
62. Guyot K., Follet-Dumoulin A., Lelievre E., Sarfati C., Rabodonirina M., Nevez G., Cailliez J.C., Camus D., Dei-Cas E. Molecular characterization of Cryptosporidium isolates obtained from humans in France. J. Clin. Microbiol. 2001, 39(10):3472-3480.
63. Haesebrouck F., Pasmans F., Chiers K., Maes D., Ducatelle R., Decostere A. Efficacy of vaccines against bacterial diseases in swine: what can we expect?. Vet. Microbiol. 2004, 100(3-4):255-268.
64. Hald B., Knudsen K., Lind P., Madsen M. Study of the infectivity of saline-stored Campylobacter jejuni for day-old chicks. Appl. Environ. Microbiol. 2001, 67(5):2388-2392.
65. Hall C. Impact of avian influenza on U.S. poultry trade relations-2002: H5 or H7 low pathogenic avian influenza. Ann. N.Y. Acad. Sci. 2004, 1026:47-53.
66. Hanlon L., Argyle D., Bain D., Nicolson L., Dunham S., Golder M.C., McDonald M., McGillivray C., Jarrett O., Neil J.C., Onions D.E. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J. Virol. 2001, 75(18):8424-8433.
67. Hannant D., Mumford J.A., Jessett D.M. Duration of circulating antibody and immunity following infection with equine influenza virus. Vet. Rec. 1988, 122(6):125-128.
68. Heath A.W. Cytokines as immunological adjuvants. Pharm. Biotechnol. 1995, 6:645-658.
69. Hershey A.E., Sorenmo K.U., Hendrick M.J., Shofer F.S., Vail D.M. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996). J. Am. Vet. Med. Assoc. 2000, 216(1):58-61.
70. Hill B.D., Blewett D.A., Dawson A.M., Wright S. Analysis of the kinetics, isotype and specificity of serum and coproantibody in lambs infected with Cryptosporidium parvum. Res. Vet. Sci. 1990, 48(1):76-81.
71. Houdijk J.G.M., Kyriazakis I., Jackson F., Huntley J.F., Coop R.L. Can an increased intake of metabolizable protein affect the periparturient relaxation in immunity against Teladorsagia circumcincta in sheep?. Vet. Parasitol. 2000, 91(1-2):43-62.
72. Huang Y.T., Teng L.J., Ho S.W., Hsueh P.R. Streptococcus suis infection. J. Microbiol. Immunol. Infect. 2005, 38(5):306-313.
73. Hunter P.R., Chalmers R.M., Syed Q., Hughes L.S., Woodhouse S., Swift L. Foot and mouth disease and cryptosporidiosis: possible interaction between two emerging infectious diseases. Emerg. Infect. Dis. 2003, 9(1):109-112.
74. Hunter S.K., Andracki M.E., Krieg A.M. Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. Am. J. Obstet. Gynecol. 2001, 185(5):1174-1179.
75. Ioannou X.P., Griebel P., Hecker R., Babiuk L.A., van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J. Virol. 2002, 76(18):9002-9010.
76. Jacobs-Reitsma W.F., van de Giessen A.W., Bolder N.M., Mulder R.W. Epidemiology of Campylobacter spp. at two Dutch broiler farms. Epidemiol. Infect. 1995, 114(3):413-421.
77. Jenkins M.C., O'Brien C., Trout J., Guidry A., Fayer R. Hyperimmune bovine colostrum specific for recombinant Cryptosporidium parvum antigen confers partial protection against cryptosporidiosis in immunosuppressed adult mice. Vaccine 1999, 17(19):2453-2460.
78. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.D., Sullivan N.J., Volchkov V.E., Fritz E.A., Daddario K.M., Hensley L.E., Jahrling P.B., Geisbert T.W. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005, 11(7):786-790.
79. Judge N.A., Mason H.S., O'Brien A.D. Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of Escherichia coli O157:H7 shedding in feces. Infect. Immun. 2004, 72(1):168-175.
80. Karch H., Tarr P.I., Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 2005, 295(6-7):405-418.
81. Kennedy, N.J., Spithill, T.W., Tennent, J., Wood, P.R. and Piedrafita, D. DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy. Vaccine 2006; 24(7):970-979.
82. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 1991, 146(2):431-437.
83. Khoury C.A., Meinersmann R.J. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine. Avian Dis. 1995, 39(4):812-820.
84. Kim B., Bowersock T., Griebel P., Kidane A., Babiuk L.A., Sanchez M., Attah-Poku S., Kaushik R.S., Mutwiri G.K. Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres. J. Control. Release 2002, 85(1-3):191-202.
85. Kim S.J., Spradbrow P.B. Administration of a vaccine prepared from the Australian V4 strain of Newcastle disease virus by aerosol and drinking water. Aust. Vet. J. 1978, 54(10):486-489.
86. Kita, J., Oyrzanowska, J., Prandota, J. and Banbura, M. XIIth World Congress on Diseases of Cattle, Utrecht, Netherlands. 1982.
87. Knott G.K.L., Erwin B.G., Classick L.G. Benefits of a clostridial vaccination program in feedlot cattle. Vet. Med. 1985, 80(6):95-97.
88. Kobayashi M., Carpenter T.E., Dickey B.F., Howitt R.E. A dynamic, optimal disease control model for foot-and-mouth disease: I. Model description. Prev. Vet. Med. 2007, 79(2-4):257-273.
89. Kobayashi M., Carpenter T.E., Dickey B.F., Howitt R.E. A dynamic, optimal disease control model for foot-and-mouth-disease: II. Model results and policy implications. Prev. Vet. Med. 2007, 79(2-4):274-286.
90. Kowalski J., Gilbert S.A., van Drunen-Littel-van den Hurk S., van den Hurk J., Babiuk L.A., Zamb T.J. Heat-shock promoter-driven synthesis of secreted bovine herpesvirus glycoproteins in transfected cells. Vaccine 1993, 11(11):1100-1107.
91. Krieg A.M., Yi A.K., Hartmann G. Mechanisms and therapeutic applications of immune stimulatory cpG DNA. Pharmacol. Ther. 1999, 84(2):113-120.
92. Krystynak R.H., Charlebois P.A. The potential economic impact of an outbreak of foot-and-mouth disease in Canada. Can. Vet. J. 1987, 28(8):523-527.
93. Llull D., Lopez R., Garcia E. Genetic bases and medical relevance of capsular polysaccharide biosynthesis in pathogenic streptococci. Curr. Mol. Med. 2001, 1(4):475-491.
94. Lumb R., Lanser J.A., O'Donoghue P.J. Electrophoretic and immunoblot analysis of Cryptosporidium oocysts. Immunol. Cell Biol. 1988, 66(Pt 5-6):369-376.
95. Lutticken D., Segers R.P., Visser N. Veterinary vaccines for public health and prevention of viral and bacterial zoonotic diseases. Rev. Sci. Tech. 2007, 26(1):165-177.
96. MacInnes J.I., Desrosiers R. Agents of the "suis-ide diseases" of swine: Actinobacillus suis, Haemophilus parasuis, and Streptococcus suis. Can. J. Vet. Res. 1999, 63(2):83-89.
97. Mac Kenzie W.R., Hoxie N.J., Proctor M.E., Gradus M.S., Blair K.A., Peterson D.E., Kazmierczak J.J., Addiss D.G., Fox K.R., Rose J.B., et al. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. N. Engl. J. Med. 1994, 331(3):161-167.
98. Maire N., Aponte J.J., Ross A., Thompson R., Alonso P., Utzinger J., Tanner M., Smith T. Modeling a field trial of the RTS,S/AS02A malaria vaccine. Am. J. Trop. Med. Hyg. 2006, 75(2 Suppl.):104-110.
99. Mantis N.J., Cheung M.C., Chintalacharuvu K.R., Rey J., Corthesy B., Neutra M.R. Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor. J. Immunol. 2002, 169(4):1844-1851.
100. Marano N., Rupprecht C., Regnery R. Vaccines for emerging infections. Rev. Sci. Tech. 2007, 26(1):203-215.
101. Marshall M., Roger P. Policy and science of FMD control: the stakeholders' contribution to decision making. A call for integrated animal disease management. J. Clin. Lab. Immunol. 2004, 53:27-38.
102. Martinez G., Harel J., Lacouture S., Gottschalk M. Genetic diversity of Streptococcus suis serotypes 2 and 1/2 isolates recovered from carrier pigs in closed herds. Can. J. Vet. Res. 2002, 66(4):240-248.
103. Matthews L., Low J.C., Gally D.L., Pearce M.C., Mellor D.J., Heesterbeek J.A., Chase-Topping M., Naylor S.W., Shaw D.J., Reid S.W., Gunn G.J., Woolhouse M.E. Heterogeneous shedding of Escherichia coli O157 in cattle and its implications for control. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(3):547-552.
104. McCauley E.H., Aulaqi N.A., Sundquist W.B., New J.C., Miller W.M. A study of the potential economic impact of foot and mouth disease in the United States. Proc. Annu. Meet. U.S. Anim. Health Assoc. 1977, 81:284-296.
105. McGavin D. Passive immunity and canine parvovirus. Websters Vet. Digest 1985, 19(1):2-3.
106. McIlroy S.G., Goodall E.A., Bruce D.W., McCracken R.M., McNulty M.S. The cost benefit of vaccinating broiler flocks against subclinical infectious bursal disease. Avian Pathol. 1992, 21(1):65-76.
107. McLauchlin J., Amar C., Pedraza-Diaz S., Nichols G.L. Molecular epidemiological analysis of Cryptosporidium spp. in the United Kingdom: results of genotyping Cryptosporidium spp. in 1,705 fecal samples from humans and 105 fecal samples from livestock animals. J. Clin. Microbiol. 2000, 38(11):3984-3990.
108. McNeal M.M., Rae M.N., Ward R.L. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 1999, 17(11-12):1573-1580.
109. McQuiston J.H., Garber L.P., Porter-Spalding B.A., Hahn J.W., Pierson F.W., Wainwright S.H., Senne D.A., Brignole T.J., Akey B.L., Holt T.J. Evaluation of risk factors for the spread of low pathogenicity H7N2 avian influenza virus among commercial poultry farms. J. Am. Vet. Med. Assoc. 2005, 226(5):767-772.
110. Mead J.R., Arrowood M.J., Sterling C.R. Antigens of Cryptosporidium sporozoites recognized by immune sera of infected animals and humans. J. Parasitol. 1988, 74(1):135-143.
111. Medema J.K., Zoellner Y.F., Ryan J., Palache A.M. Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply. Virus Res. 2004, 103(1-2):9-15.
112. Miguens L. The opinion of the production sector on the role of vaccines in the control and eradication of livestock diseases in Argentina. Rev. Sci. Tech. 2007, 26(2):479-483. 485-488.
113. Mittal S.K., Aggarwal N., Sailaja G., van Olphen A., HogenEsch H., North A., Hays J., Moffatt S. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 2000, 19(2-3):253-263.
114. Moore G.E., Guptill L.F., Ward M.P., Glickman N.W., Faunt K.K., Lewis H.B., Glickman L.T. Adverse events diagnosed within three days of vaccine administration in dogs. J. Am. Vet. Med. Assoc. 2005, 227(7):1102-1108.
115. Morein B., Abusugra I., Blomqvist G. Immunity in neonates. Vet. Immunol. Immunopathol. 2002, 87(3-4):207-213.
116. Morein B., Hu K.F., Abusugra I. Current status and potential application of ISCOMs in veterinary medicine. Adv. Drug Deliv. Rev. 2004, 56(10):1367-1382.
117. Morgan U., Weber R., Xiao L., Sulaiman I., Thompson R.C., Ndiritu W., Lal A., Moore A., Deplazes P. Molecular characterization of Cryptosporidium isolates obtained from human immunodeficiency virus-infected individuals living in Switzerland, Kenya, and the United States. J. Clin. Microbiol. 2000, 38(3):1180-1183.
118. Morgan-Ryan U.M., Fall A., Ward L.A., Hijjawi N., Sulaiman I., Fayer R., Thompson R.C., Olson M., Lal A., Xiao L. Cryptosporidium hominis n. sp. (Apicomplexa: Cryptosporidiidae) from Homo sapiens. J. Eukaryot. Microbiol. 2002, 49(6):433-440.
119. Mouzin D.E., Lorenzen M.J., Haworth J.D., King V.L. Duration of serologic response to five viral antigens in dogs. J. Am. Vet. Med. Assoc. 2004, 224(1):55-60.
120. Mouzin D.E., Lorenzen M.J., Haworth J.D., King V.L. Duration of serologic response to three viral antigens in cats. J. Am. Vet. Med. Assoc. 2004, 224(1):61-66.
121. Muller H.M., Reckmann I., Hollingdale M.R., Bujard H., Robson K.J., Crisanti A. Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes. EMBO J. 1993, 12(7):2881-2889.
122. Muneta Y., Yoshihara K., Minagawa Y., Nagata R., Yasuyuki M., Yamaguchi T., Takehara K. Bovine IL-18 ELISA: detection of IL-18 in sera of pregnant cow and newborn calf, and in colostrum. J. Immunoassay Immunochem. 2005, 26(3):203-213.
123. Murillo M., Grillo M.J., Rene J., Marin C.M., Barberan M., Goni M.M., Blasco J.M., Irache J.M., Gamazo C. A Brucella ovis antigenic complex bearing poly-epsilon-caprolactone microparticles confer protection against experimental brucellosis in mice. Vaccine 2001, 19(30):4099-4106.
124. Naylor S.W., Low J.C., Besser T.E., Mahajan A., Gunn G.J., Pearce M.C., McKendrick I.J., Smith D.G., Gally D.L. Lymphoid follicle-dense mucosa at the terminal rectum is the principal site of colonization of enterohemorrhagic Escherichia coli O157:H7 in the bovine host. Infect. Immun. 2003, 71(3):1505-1512.
125. Nielsen, R., Loftager, M. and Eriksen, L. International Pig Veterinary Society, 11th Congress, Lausanne, Switzerland. 1990.
126. Niskanen R., Lindberg A. Transmission of bovine viral diarrhea virus by unhygienic vaccination procedures, ambient air, and from contaminated pens. Vet. J. 2003, 165(2):125-130.
127. Nonnecke B.J., Waters W.R., Foote M.R., Palmer M.V., Miller B.L., Johnson T.E., Perry H.B., Fowler M.A. Development of an adult-like cell-mediated immune response in calves after early vaccination with Mycobacterium bovis bacillus Calmette-Guerin. J. Dairy Sci. 2005, 88(1):195-210.
128. Noor S.M., Husband A.J., Widders P.R. In ovo oral vaccination with Campylobacter jejuni establishes early development of intestinal immunity in chickens. Br. Poult. Sci. 1995, 36(4):563-573.
129. Normile D. Infectious diseases. WHO probes deadliness of China's pig-borne disease. Science 2005, 309(5739):1308-1309.
130. Okwumabua O., Chinnapapakkagari S. Identification of the gene encoding a 38-kilodalton immunogenic and protective antigen of Streptococcus suis. Clin. Diagn. Lab. Immunol. 2005, 12(4):484-490.
131. Paarlberg P.L., Lee J.G., Seitzinger A.H. Potential revenue impact of an outbreak of foot-and-mouth disease in the United States. J. Am. Vet. Med. Assoc. 2002, 220(7):988-992.
132. Pappo J., Ermak T.H., Steger H.J. Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology 1991, 73(3):277-280.
133. Payne L.G., Andrianov A.K. Protein release from polyphosphazene matrices. Adv. Drug Deliv. Rev. 1998, 31(3):185-196.
134. Payne L.G., Jenkins S.A., Andrianov A., Roberts B.E. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm. Biotechnol. 1995, 6:473-493.
135. Perez A.M., Thurmond M.C., Carpenter T.E. Spatial distribution of foot-and-mouth disease in Pakistan estimated using imperfect data. Prev. Vet. Med. 2006, 76(3-4):280-289.
136. Perez A.M., Thurmond M.C., Grant P.W., Carpenter T.E. Use of the scan statistic on disaggregated province-based data: foot-and-mouth disease in Iran. Prev. Vet. Med. 2005, 71(3-4):197-207.
137. Perez A.M., Ward M.P., Carpenter T.E. Control of a foot-and-mouth disease epidemic in Argentina. Prev. Vet. Med. 2004, 65(3-4):217-226.
138. Perry B.D., Kalpravidh W., Coleman P.G., Horst H.S., McDermott J.J., Randolph T.F., Gleeson L.J. The economic impact of foot and mouth disease and its control in South-East Asia: a preliminary assessment with special reference to Thailand. Rev. Sci. Tech. 1999, 18(2):478-497.
139. Perryman L.E., Jasmer D.P., Riggs M.W., Bohnet S.G., McGuire T.C., Arrowood M.J. A cloned gene of Cryptosporidium parvum encodes neutralization-sensitive epitopes. Mol. Biochem. Parasitol. 1996, 80(2):137-147.
140. Perryman L.E., Kapil S.J., Jones M.L., Hunt E.L. Protection of calves against cryptosporidiosis with immune bovine colostrum induced by a Cryptosporidium parvum recombinant protein. Vaccine 1999, 17(17):2142-2149.
141. Peters A.R., Thevasagayam S.J., Wiseman A., Salt J.S. Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV, and BRSV in experimentally infected calves. Prev. Vet. Med. 2004, 66(1-4):63-77.
142. Pfeffer A., Shaw R.J., Green R.S., Phegan M.D. The transfer of maternal IgE and other immunoglobulins specific for Trichostrongylus colubriformis larval excretory/secretory product to the neonatal lamb. Vet. Immunol. Immunopathol. 2005, 108(3-4):315-323.
143. Pieniazek N.J., Bornay-Llinares F.J., Slemenda S.B., da Silva A.J., Moura I.N., Arrowood M.J., Ditrich O., Addiss D.G. New cryptosporidium genotypes in HIV-infected persons. Emerg. Infect. Dis. 1999, 5(3):444-449.
144. Potter A.A., Klashinsky S., Li Y., Frey E., Townsend H., Rogan D., Erickson G., Hinkley S., Klopfenstein T., Moxley R.A., Smith D.R., Finlay B.B. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 2004, 22(3-4):362-369.
145. Pourbohloul B., Meyers L.A., Skowronski D.M., Krajden M., Patrick D.M., Brunham R.C. Modeling control strategies of respiratory pathogens. Emerg. Infect. Dis. 2005, 11(8):1249-1256.
146. Raggo C., Fitzpatrick D.R., Babiuk L.A., Liang X. Expression of bovine interleukin-1 beta in a bovine herpesvirus-1 vector: in vitro analysis. Virology 1996, 221(1):78-86.
147. Randolph T.F., Perry B.D., Benigno C.C., Santos I.J., Agbayani A.L., Coleman P., Webb R., Gleeson L.J. The economic impact of foot and mouth disease control and eradication in the Philippines. Rev. Sci. Tech. 2002, 21(3):645-661.
148. Rautenschlein S., Haase C. Differences in the immunopathogenesis of infectious bursal disease virus (IBDV) following in ovo and post-hatch vaccination of chickens. Vet. Immunol. Immunopathol. 2005, 106(1-2):139-150.
149. Rautenschlein S., Sharma J.M., Winslow B.J., McMillen J., Junker D., Cochran M. Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants. Vaccine 1999, 18(5-6):426-433.
150. Reber A.J., Hippen A.R., Hurley D.J. Effects of the ingestion of whole colostrum or cell-free colostrum on the capacity of leukocytes in newborn calves to stimulate or respond in one-way mixed leukocyte cultures. Am. J. Vet. Res. 2005, 66(11):1854-1860.
151. Reddy P.S., Idamakanti N., Chen Y., Whale T., Babiuk L.A., Mehtali M., Tikoo S.K. Replication-defective bovine adenovirus type 3 as an expression vector. J. Virol. 1999, 73(11):9137-9144.
152. Reddy P.S., Idamakanti N., Hyun B.H., Tikoo S.K., Babiuk L.A. Development of porcine adenovirus-3 as an expression vector. J. Gen. Virol. 1999, 80(Pt 3):563-570.
153. Rehg J.E. Anticryptosporidial activity of lasalocid and other ionophorous antibiotics in immunosuppressed rats. J. Infect. Dis. 1993, 168(6):1566-1569.
154. Reid G. Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. Vaccine 1992, 10(9):597-602.
155. Reperant J.M., Naciri M., Iochmann S., Tilley M., Bout D.T. Major antigens of Cryptosporidium parvum recognised by serum antibodies from different infected animal species and man. Vet. Parasitol. 1994, 55(1-2):1-13.
156. Rice B.E., Rollins D.M., Mallinson E.T., Carr L., Joseph S.W. Campylobacter jejuni in broiler chickens: colonization and humoral immunity following oral vaccination and experimental infection. Vaccine 1997, 15(17-18):1922-1932.
157. Riising H.J., van Empel P., Witvliet M. Protection of piglets against atrophic rhinitis by vaccinating the sow with a vaccine against Pasteurella multocida and Bordetella bronchiseptica. Vet. Rec. 2002, 150(18):569-571.
158. Rossides S.C. A farming perspective on the 2001 foot and mouth disease epidemic in the United Kingdom. Rev. Sci. Tech. 2002, 21(3):831-838.
159. Rydell N., Sjoholm I. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 2004, 22(9-10):1265-1274.
160. Sagodira S., Iochmann S., Mevelec M.N., Dimier-Poisson I., Bout D. Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses. Parasite Immunol. 1999, 21(10):507-516.
161. Sahin O., Luo N., Huang S., Zhang Q. Effect of Campylobacter-specific maternal antibodies on Campylobacter jejuni colonization in young chickens. Appl. Environ. Microbiol. 2003, 69(9):5372-5379.
162. Samuel A.R., Knowles N.J. Foot-and-mouth disease virus: cause of the recent crisis for the UK livestock industry. Trends Genet. 2001, 17(8):421-424.
163. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccines 2005, 23(30):3876-3886.
164. Schudel A., Lombard M. OIE/FAO International Scientific Conference on Avian Influenza. Emerg. Inf. Dis. 2006, 12(11):1.
165. Schultz-Cherry S., Dybing J.K., Davis N.L., Williamson C., Suarez D.L., Johnston R., Perdue M.L. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 2000, 278(1):55-59.
166. Scott H.M., Atkins G., Willows B., McGregor R. Effects of 2 commercially-available 9-way killed vaccines on milk production and rectal temperature in Holstein-Friesian dairy cows. Can. Vet. J. 2001, 42(10):793-798.
167. Selke M., Meens J., Springer S., Frank R., Gerlach G.F. Immunization of pigs to prevent disease in humans: construction and protective efficacy of a Salmonella enterica serovar Typhimurium live negative-marker vaccine. Infect. Immun. 2007, 75(5):2476-2483.
168. Shane S.M., Stern N.J. Campylobacter infection. Diseases of Poultry 2003, 615-630. Iowa State Press, Ames, IA. Y.M. Saif, H.J. Barnes, J.R. Glisson, A.M. Fadly, L.R. McDougald, D.E. Swayne (Eds.).
169. Shewen P.E., Wilkie B.N. Cytotoxin of Pasteurella haemolytica acting on bovine leukocytes. Infect. Immun. 1982, 35(1):91-94.
170. Shiilegdamba E., Carpenter T.E., Perez A.M., Thurmond M.C.
171. Smith H.E., Vecht U., Wisselink H.J., Stockhofe-Zurwieden N., Biermann Y., Smits M.A. Mutants of Streptococcus suis types 1 and 2 impaired in expression of muramidase-released protein and extracellular protein induce disease in newborn germfree pigs. Infect. Immun. 1996, 64(10):4409-4412.
172. Stern N.J., Meinersmann R.J., Dickerson H.W. Influence of antibody treatment of Campylobacter jejuni on the dose required to colonize chicks. Avian Dis. 1990, 34(3):595-601.
173. Sultan A.A., Thathy V., Frevert U., Robson K.J., Crisanti A., Nussenzweig V., Nussenzweig R.S., Menard R. TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell 1997, 90(3):511-522.
174. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., Berzofsky J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990, 344(6269):873-875.
175. Tamber H., Johansen P., Merkle H.P., Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. 2005, 57(3):357-376.
176. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365(9464):1073-1086.
177. Thompson D., Muriel P., Russell D., Osborne P., Bromley A., Rowland M., Creigh-Tyte S., Brown C. Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. Rev. Sci. Tech. 2002, 21(3):675-687.
178. Tilley M., Upton S.J., Fayer R., Barta J.R., Chrisp C.E., Freed P.S., Blagburn B.L., Anderson B.C., Barnard S.M. Identification of a 15-kilodalton surface glycoprotein on sporozoites of Cryptosporidium parvum. Infect. Immun. 1991, 59(3):1002-1007.
179. Tizard I. Veterinary Immunology: An Introduction 2004, W. B. Saunders, New York. 7th ed.
180. Townsend H.G., Penner S.J., Watts T.C., Cook A., Bogdan J., Haines D.M., Griffin S., Chambers T., Holland R.E., Whitaker-Dowling P., Youngner J.S., Sebring R.W. Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet. J. 2001, 33(7):637-643.
181. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. 1995, 6:495-524.
182. Ungar B.L.P. Cryptosporidiosis in humans ( Homo sapiens). Cryptosporidiosis of Man and Animals 1990, 60-82. CRC Press, Boca Raton, FL. J.P. Dubey, C.A. Speer, R. Fayer (Eds.).
183. Vallat B., Mallet E. Ensuring good governance to address emerging and re-emerging animal disease threats: supporting the veterinary services of developing countries to meet OIE international standards on quality. Rev. Sci. Tech. 2006, 25(1):389-401.
184. van Donkersgoed J., Dubeski P.L., Aalhus J.L., VanderKop M., Dixon S., Starr W.N. The effect of vaccines and antimicrobials on the formation of injection site lesions in subprimals of experimentally injected beef calves. Can. Vet. J. 1999, 40(4):245-251.
185. van Donkersgoed J., Hancock D., Rogan D., Potter A.A. Escherichia coli O157:H7 vaccine field trial in 9 feedlots in Alberta and Saskatchewan. Can. Vet. J. 2005, 46(8):724-728.
186. van Drunen Littel-van den Hurk S., Babiuk S.L., Babiuk L.A. Strategies for improved formulation and delivery of DNA vaccines to veterinary target species. Immunol. Rev. 2004, 199:113-125.
187. van Immerseel F., Methner U., Rychlik I., Nagy B., Velge P., Martin G., Foster N., Ducatelle R., Barrow P.A. Vaccination and early protection against non-host-specific Salmonella serotypes in poultry: exploitation of innate immunity and microbial activity. Epidemiol. Infect. 2005, 133(6):959-978.
188. van Oirschot J.T. Classical attenuated vaccines. Veterinary Vaccinology 1997, 260-262. Elsevier, New York. J.B.P.P. Pastoret, P. Vannier, C. Verschueren (Eds.).
189. van Oirschot J.T., Rziha H.J., Moonen P.J., Pol J.M., van Zaane D. Differentiation of serum antibodies from pigs vaccinated or infected with Aujeszky's disease virus by a competitive enzyme immunoassay. J. Gen. Virol. 1986, 67(Pt 6):1179-1182.
190. van Rooijen G.J., Moloney M.M. Plant seed oil-bodies as carriers for foreign proteins. Biotechnology (N.Y.) 1995, 13(1):72-77.
191. von Overbeck J. Insurance and epidemics: SARS, West Nile virus and Nipah virus. J. Insur. Med. 2003, 35(3-4):165-173.
192. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000, 18(17):1755-1762.
193. Wen S.X., Teel L.D., Judge N.A., O'Brien A.D. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 2006, 24(8):1142-1148.
194. Westergaard J.M. Preparedness for major OIE-listed epidemics: implementation of simulation exercises. Zoonoses Public Health 2008, 55(1):37-41.
195. Whiting T.L. Foreign animal disease outbreaks, the animal welfare implications for Canada: risks apparent from international experience. Can. Vet. J. 2003, 44(10):805-815.
196. Widders P.R., Perry R., Muir W.I., Husband A.J., Long K.A. Immunisation of chickens to reduce intestinal colonisation with Campylobacter jejuni. Br. Poult. Sci. 1996, 37(4):765-778.
197. Widders P.R., Thomas L.M., Long K.A., Tokhi M.A., Panaccio M., Apos E. The specificity of antibody in chickens immunised to reduce intestinal colonisation with Campylobacter jejuni. Vet. Microbiol. 1998, 64(1):39-50.
198. Wikingsson L., Sjoholm I. Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. Vaccine 2002, 20(27-28):3355-3363.
199. Wisselink H.J., Stockhofe-Zurwieden N., Hilgers L.A., Smith H.E. Assessment of protective efficacy of live and killed vaccines based on a non-encapsulated mutant of Streptococcus suis serotype 2. Vet. Microbiol. 2002, 84(1-2):155-168.
200. Withanage G.S., Wigley P., Kaiser P., Mastroeni P., Brooks H., Powers C., Beal R., Barrow P., Maskell D., McConnell I. Cytokine and chemokine responses associated with clearance of a primary Salmonella enterica serovar Typhimurium infection in the chicken and in protective immunity to rechallenge. Infect. Immun. 2005, 73(8):5173-5182.
201. Witter R.L., Fadly A.M. Reduction of horizontal transmission of avian leukosis virus subgroup J in broiler breeder chickens hatched and reared in small groups. Avian Pathol. 2001, 30(6):641-654.
202. Woods K.M., Nesterenko M.V., Upton S.J. Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. Ann. Trop. Med. Parasitol. 1996, 90(6):603-615.
203. Wu J.Y., Gardner B.H., Murphy C.I., Seals J.R., Kensil C.R., Recchia J., Beltz G.A., Newman G.W., Newman M.J. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 1992, 148(5):1519-1525.
204. YongQing H., YuMing G., YuPing Z., Cheng J., JingYang Z. Effect of different dietary levels of protein, lysine, methionine and threonine on immune function in early weaned piglets. Chin. J. Anim. Sci. 2001, 37(4):18-20.
205. Zelphati O., Szoka F.C. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. 1996, 13(9):1367-1372.
206. Zinsstag J., Weiss M.G. Livestock diseases and human health. Science 2001, 294(5542):477.